Psoriasis Is Treated as a Skin Disease. It Behaves Like a Systemic One.
The plaques are what the patient came in about. The elevated cardiovascular risk, the undiagnosed metabolic disease and the laboratory obligations attached to their biologic are what nobody is holding.
Dermatology qualifies for these programs through the systemic therapy load and the comorbidity that travels with inflammatory skin disease, not through the skin itself. That distinction is what CareNexa builds the protocol around.
The Opportunity
The Second Condition Is Usually Already There
Eligibility questions stall in most specialties on whether a qualifying second condition exists. In a dermatology panel on systemic therapy it almost always does. Moderate to severe psoriasis and hidradenitis suppurativa carry documented cardiometabolic burden, and immunosuppressive therapy adds monitoring obligations that behave like a chronic condition in their own right.
What is missing is not the diagnosis. It is anyone managing it between visits. Many of these patients see you three or four times a year and their primary care physician not at all, which makes dermatology the practice that is actually in contact when something drifts.
Who Qualifies
Which of Your Patients Qualify
The populations where systemic treatment creates continuous management work:
Moderate to severe psoriasis on systemic or biologic therapy:
The core population. Laboratory obligations, access logistics and cardiometabolic risk all run continuously alongside the skin disease.
Psoriasis or hidradenitis suppurativa with metabolic comorbidity:
Where diabetes, obesity or cardiovascular disease is documented, undertreated, and connected to the condition you are managing.
Atopic dermatitis on systemic therapy:
Where tolerability in the first months and laboratory monitoring on newer oral agents decide whether the patient stays on treatment.
Hidradenitis suppurativa:
High comorbidity burden, difficult access to biologics, frequent flares and repeated procedural care between appointments.
Patients on methotrexate, cyclosporine or prolonged systemic steroids:
Laboratory monitoring, blood pressure and renal surveillance are requirements attached to the drug rather than optional extras.
Autoimmune blistering disease on immunosuppression:
Where infection risk, steroid exposure and monitoring schedules mirror what rheumatology carries.
Melanoma and high risk skin cancer survivors with a second chronic condition:
Where surveillance intervals slip quietly and the second condition is what makes structured management billable.
And who we would leave out:
Acne, rosacea and conditions managed topically with no systemic therapy and no second qualifying condition.
Patients seen once for a procedure with no ongoing management requirement.
Patients stable for years on a topical regimen they use reliably without support.
Program Fit
Where Each Program Does the Work
CCM is the program in dermatology
The recurring work is drug safety and access, and our care team carries it rather than yours. Laboratory schedules for methotrexate, cyclosporine and the newer oral agents. Tuberculosis screening and vaccination timing before and during biologic therapy. Prior authorization, specialty pharmacy delivery and copay assistance. Injection and infusion scheduling. Each is a protocol driven task with a deadline attached.
The second half is comorbidity coordination. Many of these patients have no active primary care relationship, which means the lipid panel, the A1c and the blood pressure check nobody has ordered. A coordinator can get those scheduled and get the results in front of somebody.
RPM is limited, and photographs are not RPM
Blood pressure monitoring has a legitimate place for patients on cyclosporine or prolonged systemic steroids, and for the cardiometabolic share of an inflammatory disease panel. Weight monitoring supports the same group. Beyond that there is no daily physiologic measurement in dermatology that drives a decision. Where a device is indicated we supply it, and it costs the practice nothing.
Image review is a different construct entirely. Store and forward teledermatology, asynchronous consultation and photograph based assessment have their own requirements and their own codes, and none of them are remote physiologic monitoring. We will build a program on the care management side and say plainly where the device case runs out.
Monthly Touchpoint
What the Monthly Touchpoint Actually Covers
Dermatology monthly contact is built around the drug rather than the rash:
Laboratory monitoring compliance.
Whether required labs were drawn on schedule for the agent the patient is on, results reviewed against your parameters, and the next draw booked.
Access and supply continuity.
Authorization status, specialty pharmacy delivery, copay assistance and injection or infusion scheduling. Interruptions here are the most common reason effective therapy stops.
Adherence and application technique.
How much topical therapy is being used, where, and how often. Patients abandon regimens over stinging, greasiness and the sheer time a large body surface takes, and they rarely mention it.
Adherence and application technique.
How much topical therapy is being used, where, and how often. Patients abandon regimens over stinging, greasiness and the sheer time a large body surface takes, and they rarely mention it.
Comorbidity screening follow through.
Lipids, A1c and blood pressure, whether a primary care relationship exists at all, and whether the referral you made was ever attended.
Disease activity and flare check.
Itch, sleep disruption, involved body surface and joint symptoms, asked as structured questions with escalation criteria you define.
Clinical value
What Changes
The most common finding is not clinical. A patient reports that the ointment is not working. The coordinator asks how much they are using, over what area and for how long, and learns they stopped after two weeks because it stung and they assumed that meant it was wrong. That patient was on their way to being escalated to a systemic agent for a treatment failure that never happened.
The second is the comorbidity nobody was looking at. Psoriasis patients who have not had a lipid panel or an A1c in years get one, because somebody on a monthly call noticed there was no primary care physician in the picture. It is unglamorous work and it is the part of these programs that changes long term risk rather than short term appearance.
Photographs are not remote physiologic monitoring. Image capture, asynchronous review and store and forward teledermatology are valuable and they are governed by their own billing constructs with their own requirements. If a vendor is presenting a photo app as a remote monitoring program, ask which physiologic measurement is being transmitted and by which device. Your billing lead should confirm the answer before anything launches.
Questions Dermatology Practices Ask
Most of our volume is procedural and episodic. Do we really have a chronic care panel?
Not across the whole practice, and we would not claim otherwise. The program sits on your systemic and biologic therapy patients, which in most dermatology practices is a few hundred people carrying continuous monitoring obligations. That is the cohort, and it is usually larger than practices assume once we screen your records against the systemic therapy list rather than the diagnosis list.
Can a coordinator assess a rash over the phone?
No, and we do not ask them to. They run structured symptom questions against criteria you define, capture what the patient reports, and route anything meeting your escalation criteria to your clinical staff. Anything meeting your escalation criteria reaches your clinical staff through the same dashboard the rest of the program runs on, and any image the patient sends goes through your own review process rather than the coordinator’s judgment.
Our patients see us more often than their primary care physician. Should we be the biller?
For a patient on systemic therapy whose dominant management burden sits with you, usually yes, and most primary care physicians agree readily when asked. We check who is already billing before enrolling anyone, and where it is genuinely ambiguous we ask rather than assume.
We already have a biologics coordinator. Is this duplicative?
It can be. If your authorization and specialty pharmacy work is already running well, we would rather build the program around laboratory monitoring, comorbidity coordination and flare triage than duplicate a function you have staffed. We would rather scope it accurately than sell you both. The staffing layer comes from us either way, so the only question is which part of the work we take on.
Start With Your Systemic and Biologic Therapy Patients
They carry the monitoring obligations, the access problems and the comorbidity burden in one cohort, which makes them the group where a structured program proves itself fastest. We staff it, document it to CMS requirements and export the billing, so what the practice supplies is the patient list and the rules for escalation.